Ten years of cyclosporine use in renal transplantation: A single-center experience with 479 renal transplants

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S177-S180

  Lucan, M ^a   Iacob, G ^a   Lucan, C ^a   Lapusan C ^a   Munteanu, A ^a   Sirbu S ^a  

^a Clinical Institute of Urology   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; EXPERIENCE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; SURVIVAL RATE; TREATMENT WITHDRAWAL;

ADULT; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1642394934     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.12.025     Document Type: Article

References (14)

1. Schwartz R., Dameshek W. Drug-induced immunologic tolerance. Nature. 183:1959;1682.
2. Murray J.E., Merrill J.P., Harrison J.H., et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med. 268:1963;1315.
3. The EBPG Expert Group on Renal Transplantation. Initial and maintenance immunosuppressive treatment. Nephrol Dial Transplant. 15:(suppl 7):2000;64.
4. Myers B.D., Ross J., Newton L., et al. Cyclosporin-associated chronic nephropathy. N Engl J Med. 311:1984;699.
5. Clipstone N.A., Crabtree G.R. Calcineurin is the key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drug. Ann NY Acad Sci USA. 696:1993;20.
6. Warrens A.N. The evolving role of mycophenolate mofetil in renal transplantation. QJM. 93:2000;15.
7. Ojo A.O., Meier-Kriesche H.-U., Hanson J.A., et al. Mycophenolate mofetil reduces late allograft loss independent of acute rejection. Transplantation. 69:2000;2405.
8. Cole E., Maham N., Cardella C., et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 72:2003;2086.
9. Sehgal S.N., Molnar-Kimbar K., Ocain T.D., et al. Rapamycin. A novel immunosuppressive macrolide. Med Res Rev. 14:1994;1.
10. Andoh T.F., Burdmann E.A., Fransechini N., et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 50:1996;1110.
11. Murgia M.G., Jordan S., Kahan B.D. The side effect profile of sirolimus a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49:1996;209.
12. Kahan B.D., Camardo J.S. Rapamycin clinical results and future opportunities. Transplantation. 72:2001;1181.
13. Backman L., Morales J.M. Is non-nephrotoxic immunosuppression a possibility? Transplantation. 69:2000;SS27.
14. Saunders R.N., Metcalfe M.S., Nicholson M.L. Rapamycin in transplantation a review of the evidence. Kidney Int. 59:2001;3.